TLR6 and irritable bowel syndrome: This conclusion might indicate a potential target for future IBD treatment, since TLR6-deficient mice manifest decreased Th1 and Th17 responses in gut-associated lymphoid tissue compared to their TLR6-sufficient counterparts (23).